SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure as investors react to a combination of disappointing quarterly delivery figures, J.P. Morgans analyst downgrade citing major downside risk, and growing community speculation that capital is rotating out of the stock in anticipation of the upcoming SpaceX IPO. Amidst a volatile geopolitical climate, discussions on the platform are dominated by debates over leadership, the company's long-term competitive moat in the EV and AI space, and highly active trading around the stock's technical support levels.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as investors debate the company's ability to overcome manufacturing hurdles at its Malaysia facility, specifically relating to laser dicing and production yields. While the community remains polarized between those viewing the stock as a distressed 'zombie' play and long-term believers citing institutional ownership and potential partnerships, high short interest and anticipation of upcoming purchase orders keep sentiment highly volatile.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Fubo is facing intense debate as investors weigh the company's long-term financial guidance against a sharp price decline following a recent reverse stock split. The community remains deeply polarized, with some bulls pointing to sports-streaming dominance as a reason to hold, while skeptical traders focus on persistent bearish momentum and management's silence as catalysts for further short-selling.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as investors cheer the company's strategic pivot into AI infrastructure and recent high-profile production orders for its ultra-high-power testing systems. The community is heavily focused on the company's role as a critical bottleneck gatekeeper for reliability in the hyperscale data center supply chain, fueling bullish sentiment around upcoming earnings and guidance.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

Buttcoin

Buttcoin is gaining attention as a long-standing meme project, with the community actively debating whether its 15-year history of mocking the crypto industry translates into lasting value or a satirical phenomenon. Supporters are pushing the asset as a nostalgic, culture-driven alternative to mainstream tokens, while others view the surrounding social media fervor as a cautionary example of speculative retail behavior.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

TSLL is drawing heavy trader interest as the community debates whether recent volatility and price action represent a durable support level or a setup for further downside. Investors are actively discussing the impact of leverage decay, institutional algorithmic manipulation, and conflicting sentiment regarding the long-term viability of high-growth technology promises.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending as institutional investors and whales navigate heightened volatility, with intense community debate over recent ETF accumulation patterns, broader macro pressures, and the potential impact of ongoing market manipulation allegations. The stock remains a focal point for both bulls eyeing long-term adoption and bears focused on short-term price weakness and systemic risks.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending as investors actively debate its long-term potential as a supplier for the Co-Packaged Optics (CPO) market, with community discussions focused on its strategic integration into next-generation AI data center roadmaps. While shareholders remain divided over the company's historical management performance, recent news cycles highlighting its role in emerging optical component supply chains have reignited interest in its growth prospects.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is experiencing significant volatility as investors weigh a strong quarterly earnings beat and positive guidance against broader solar sector headwinds and concerns over upcoming debt obligations. The community remains deeply polarized, with some bulls highlighting the long-term potential of residential solar and battery storage in an AI-driven energy economy, while others express frustration over the stock's persistent downtrend, regulatory uncertainty, and aggressive short-selling activity.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is trading at significantly higher levels following the FDA approval of VYKAT XR, the first therapy to treat hyperphagia in Prader-Willi syndrome patients. The community is actively debating the stock's future valuation, with discussions focusing on the success of the commercial launch, potential buyout interest, and the robustness of the company's patent and safety profile against persistent short-seller criticism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge PR Newswire VANCOUVER, BC, Oct. 15, 2025 Equity Insider News...

CytoMed Therapeutics (GDTC) announced on Tuesday that it has submitted a cash bid for an undisclosed sum to the joint administrators of TC BioPharm, effective October 2, for the potential acquisition of its assets.The proposed acquisition will strengthen and deepen CytoMed’s expertise and knowledge in using allogeneic cell therapies for cancer treatment, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166116/0/en/CytoMed-makes-cash-bid-for-potential-acquisition-of-TC-BioPharm-Limited-s-relevant-assets.html">said</a>. The company added that this will help it accelerate its commercialization timeline.TC BioPharm and CytoMed are both clinical-stage biopharmaceutical companies engaged in the research and development of donor-derived allogeneic gamma delta T cells for cancer treatment. While TC BioPharm has completed an early-stage clinical trial, CytoMed is currently conducting an early-stage trial in Singapore, evaluating its chimeric antigen receptor (CAR) T cells for a broad range of liquid and solid cancers.The proposed acquisition will be funded by internal resources, the Singapore-based CytoMed said. Shares of the company traded 19% higher at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GDTC">GDTC stock</a> rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_14_at_11_07_48_AM_png_d20bc36299.webp" alt="GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits" width="623" height="63"><figcaption>GDTC's Sentiment Meter and Message Volume as of 11:08 a.m. ET on Oct. 14, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock might be gearing up for a breakout soon.<stembedurl>https://stocktwits.com/Nova_Trades/message/632225590</stembedurl>CytoMed acquired certain assets of Cellsafe International Sdn Bhd, a Malaysian cord blood bank, in October 2024. The acquisition included a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment with more than 12,000 cord blood units, and two freehold real estate properties in which the operation is situated.TC BioPharm is a unit of TC BioPharm Holdings Plc, which was listed on the Nasdaq until March earlier this year. The company said earlier this month that its directors have appointed Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP as joint administrators to its unit to explore options for the sale of the business and assets. The company also said that the parent company continues to operate as usual.GDTC stock is down by 33% this year and up by about 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/candel-therapeutics-enters-130-million-dollar-loan-facility-to-advance-lead-product-candidate-in-treatment-of-lung-cancer/ch6mpu5R3mm">Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did CytoMed Therapeutics Stock Jump 19% Today?

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 

Equity

The company said that the proposed acquisition of TC BioPharm will strengthen and deepen its expertise and knowledge in using allogeneic cell therapies for cancer treatment. 


CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Current Price	$0.9619
Prev Close	$0.9882
Open	$1.00
Dividend Yield	0.00%
50-Day Moving Average	$1.01
Beta	0.00
Avg. Volume	10,128.29
PE Ratio	-3.78

52-Week High	$3.68
52-Week Low	$0.7282
Market Capitalization	$11.6M
EPS (Annual)	-$0.2616
Price to Book	2.30
Revenue Per Employee	$5,911.17

GDTC
CYTOMED THERAPEUTICS LIMITED

Feed

News

Sentiment

Fundamentals

Info

Latest GDTC News

GDTCCYTOMED THERAPEUTICS LIMITED